## Dermatology (drugs Si-St)

(Siliq<sup>™</sup>, Simponi<sup>®</sup>, Skyrizi<sup>™</sup>, Stelara<sup>®</sup>)



For Simponi ARIA®, see Intravenous TNF-Alpha Inhibitor Form  Prescriber + Shipping Information						
Patient name:	DOB:		Prescriber name:			
Language: Wt: Qkg Qlbs Ht:Qcm Qin Address:						
Address:				City:		
Phone: Alternate: Phone:				Alte	rnate:	
Caregiver name:	Caregiver name: Relation: Fax:					
Local pharmacy:						
Insurance plan: Plan ID: If shipping to prescriber: ☐ First Fill ☐ Always Never						
Please fax a copy of front and back of the insurance card(s).  Clinical Information (Please fax all portions clinical and lab information)						
Clinical Information (Please fax all pertinent clinical and lab information)  Diagnosis: □ L40.0 (Psoriasis vulgaris/Plaque Psoriasis/Nummular Psoriasis) □ L40.8 (Other psoriasis)						
□ L40.9 (Psoriasis, unspecified) □ L40.5 (Psoriatic arthritis) □ L73.2 (Hidradenitis Suppurativa) □						
Diagnosis Date: TB test: □ Yes □ No Neg. Test Date: HBV: □ Yes □ No If yes, currently treated: □ Yes □ No						
BSA affected (%): Affected areas: Delms Soles Head Neck Genitalia						
Prior Therapy	rior Therapy			Approximate Start Dat	e Approximate End	Date
Comorbidities:						
Concomitant Medications:						
Allergies:  NKDA  Other:						
Has the patient received their starter dose(s)/kit? Yes; Start Date No						
Prescription Quantity Refill						
§ Cimzia®, Cosentyx®, Dupixent®, Enbrel®, Humira®, Ilumya™, Orencia®, and Otezla® are listed alphabetically on respective forms §						
Siliq <sup>™</sup> (brodalumab)	Inject 210 mg subcu	t on weeks 0, 1, and 2 followed by 210 r	ng subcut every	4 × 240 m = /4 5 ml	PFS	0
	2 weeks thereafter	•		4 x 210 mg/1.5 mL	PF5	U
	Inject 210 mg subcut every 2 weeks			2 x 210 mg/1.5 mL	PFS	
Simponi <sup>®</sup> (golimumab)	Psoriatic Arthritis: Inject 50 mg subcut once a month			1 x 50 mg/0.5 mL	PFS Autoinjector	
Skyrizi <sup>™</sup> (risankizumab-rzaa)	Inject 150 mg subcut at week 0, week 4, then every 12 weeks thereafter			2 x 75 mg/0.83 mL	PFS	0
	Inject 150 mg subcut at week 4 then every 12 weeks thereafter			2 x 75 mg/0.83 mL	PFS	
Stelara <sup>®</sup> (ustekinumab) Adolescent - 12-17 years old	Inject 0.75 mg/kg x kg subcut on Day 1 (<60kg)			1 x 45 mg/0.5 mL	SDV	
	Inject 45 mg subcut on Day 1 (60 to ≤ 100 kg)			1 x 45 mg/0.5 mL	PFS	0
	Inject 90 mg subcut on Day 1 (> 100 kg)			1 x 90 mg/1 mL	110	
	Inject 0.75 mg/kg x kg subcut on Day 29 and every 12 weeks thereafter (< 60 kg)			1 x 45 mg/0.5 mL	SDV	
	Inject 45 mg subcut on Day 29 and every 12 weeks thereafter (60 to ≤ 100 kg)			1 x 45 mg/0.5 mL	_	
	Inject 90 mg subcut on Day 29 and every 12 weeks thereafter (60 to ≤ 100 kg			1 x 90 mg/1 mL	ÚØÙ	
Stelara <sup>®</sup> (ustekinumab) 5 Xi `h	Inject 45 mg subcut on Day FÁ⊈ 100 kgD			1 x 45 mg/0.5 mL		_
	Inject /e mg subcut on Day F (N 100 kgD			1 x 90 mg/1 mL	ÚØÙ 0	0
	Inject 45 mg subcut on Day 29 and every 12 weeks thereafter (≤ 100 kg)			1 x 45 mg/0.5 mL		
37111	Inject 90 mg subcut on Day 29 and every 12 weeks thereafter (> 100 kg)			1 x 90 mg/1 mL	ÚØÙ	
§ Taltz®, Tremfya®, Xeljanz®, and Xeljanz® XR are listed alphabetically on respective forms§						
Injection Training Provided by: Physician's Office Pharmacy Other:						
Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise:						
Prescriber's Signature:						
I authorize Thrifty White Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to Thrifty White Pharmacy						